OBJECTIVE: A phase II study was performed to assess the activity of @entity901 plus @entity1487 ( @entity1487 ) modulated by @entity4181 , as second-line treatment in locally advanced or metastatic @entity420 pretreated with @entity136 -containing schedule. METHODS: @entity1 received weekly intravenous infusions of @entity901 40 mg/m, @entity1487 500 mg/m, and @entity4181 250 mg/m (3 weeks on, 1 week off). RESULTS: Twenty-three @entity1 affected with metastatic (16) or locally advanced (7) @entity420 were involved in this study. A total of 148 weeks of chemotherapy was delivered (median 2 courses each @entity1 ). Among 17 assessable @entity1 , no objective response was registered and 4 @entity1 had stable disease, whereas 13 had @entity5 progression. Median duration of stable disease was 14 weeks. Median @entity74 ( @entity2106 ) was 11.6 weeks [95% confidence interval (CI), 7.6-5.6]. Kaplan-Meier estimated median overall survival (OS) was 17.1 week (95% CI, 4.0-30.1) and 3 months survival rate was 69.6%. Seven @entity1 experienced grade 3 to 4 @entity137 . The regimen was associated with 36% clinical benefit. CONCLUSIONS: The median @entity2106 and median OS in this population with poor prognosis suggests some activity, however, only further investigations will be able to establish the clinical value of this combination.

XXXX , @entity1487 , and @entity4181 as second-line treatment for advanced pancreatic cancer.

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity420 :: ('MESH:D000230', 'Disease') :: ['pancreas adenocarcinoma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['time to progression of disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity2106 :: ('MESH:D011697', 'Disease') :: ['TTP'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity901 :: (MESH:C030110,Chemical) :: ['Oxaliplatin']
